A Randomized, Double-blind, Multicenter Clinical Study to Evaluate Efficacy and Safety of Fimasartan/Hydrochlorothiazide Combination-therapy in Comparison With Fimasartan Monotherapy for Essential Hypertension Patients Not Controlled by Fimasartan 60mg(Phase 3)

NCT01258673 Phase 3 COMPLETED

The purpose of this study is to evaluate the antihypertensive efficacy and safety of Fimasartan/Hydrochlorothiazide combination 60/12.5mg\~120/12.5mg in patients with essential hypertension who are not controlled by fimasartan 60mg.

Details

Lead sponsor	Boryung Pharmaceutical Co., Ltd
Phase	Phase 3
Status	COMPLETED
Enrolment	263
Start date	2010-11

Conditions

• Essential Hypertension

Interventions

• Fimasartan/HCTZ combination
• Fimasartan

Primary outcomes

• Diastolic Blood Pressure — 4week

Countries

South Korea